Wrpri LLC — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$600	1
2019	Research	$18,393	4

Breakdown

Who paid Research payments · program years 2019–2025

Takeda Pharmaceuticals U.S.A., Inc. $18,393 4 payments
AbbVie, Inc. $600 1 payment

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder $18,393 4 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension $600 1 payment

What the money was spent on Research payments · program years 2019–2025

Other $18,393 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.